M&A Deal Summary

Eisai Acquires AkaRx

On January 6, 2010, Eisai acquired life science company AkaRx for 255M USD

Acquisition Highlights
  • This is Eisai’s 1st transaction in the Life Science sector.
  • This is Eisai’s largest (disclosed) transaction.
  • This is Eisai’s 1st transaction in the United States.
  • This is Eisai’s 1st transaction in New Jersey.
Investment Fate
  • AkaRx was divested to a consortium of buyers in 2016.

M&A Deal Summary
Date 2010-01-06
Target AkaRx
Sector Life Science
Buyer(s) Eisai
Deal Type Add-on Acquisition
Deal Value 255M USD

Target

AkaRx

Paramus, New Jersey, United States
AkaRx, Inc. is a developer of Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Eisai

Woodcliff Lake, New Jersey, United States
Category Company
Founded 1995
Sector Life Science
DESCRIPTION

Eisai, Inc. is a pharmaceutical company focuses on neurology, gastrointestinal disorders and oncology/critical care.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 2
Year (2010) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-30 AkaRx

Paramus, New Jersey, United States

AkaRx, Inc. is a developer of Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist.

Sell -
Mergr

Product

Company

Legal